AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27125779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised magnesium sulphate
Number of subjects: 0
Study 27125779 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 24417584 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Insertion Technology (RIT) colonoscopes
Number of subjects: 242
Study 24417584 — intervention group
Group type: COMPARATOR
Intervention: Regular non-RIT colonoscopes
Number of subjects: 242
Study 24417584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 242
Study 22663772 — intervention group
Group type: EXPERIMENTAL
Intervention: Trajectory guidance
Number of subjects: 0
Study 22663772 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual guidance
Number of subjects: 0
Study 22663772 — intervention group
Group type: EXPERIMENTAL
Intervention: Path guidance
Number of subjects: 0
Study 22663772 — intervention group
Group type: EXPERIMENTAL
Intervention: All training modalities
Number of subjects: 0
Study 20206078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine CR 40 mg (NR)
Number of subjects: 30
Study 20206078 — intervention group
Group type: COMPARATOR
Intervention: Benidipine 4 mg (BD)
Number of subjects: 30
Study 20206078 — intervention group
Group type: COMPARATOR
Intervention: Comparison of NR vs BD
Number of subjects: 30
Study 18600389 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 528
Study 18600389 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 528
Study 18600389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 16812979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual renin-angiotensin system blockade (Valsartan added to standard therapy including ACE inhibitor and beta blocker)
Number of subjects: 44
Study 16812979 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ACE inhibitor and beta blocker)
Number of subjects: 44
Study 11730274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (2.5 microg/kg/min)
Number of subjects: 48
Study 11730274 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 48
Study 9205020 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (interval cycle and treadmill walking; 5 times/week for 3 weeks)
Number of subjects: 18
Study 9205020 — intervention group
Group type: COMPARATOR
Intervention: Activity restriction (3 weeks)
Number of subjects: 18
Study 7959238 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/day olsalazine
Number of subjects: 198
Study 7959238 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/day olsalazine
Number of subjects: 198
Study 7959238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/day olsalazine
Number of subjects: 198
Study 7959238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/day olsalazine in patients with proctitis
Number of subjects: 198
Study 7959238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/day olsalazine in patients in remission for less than 12 months
Number of subjects: 198
Study 2960577 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate/clotrimazole/gentamicin
Number of subjects: 67
Study 2960577 — intervention group
Group type: COMPARATOR
Intervention: Flumethasone pivalate/clioquinol
Number of subjects: 67
Study 2960577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 67
Study 28687911 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsy using mpMRI-TRUS fusion
Number of subjects: 100
Study 28687911 — intervention group
Group type: COMPARATOR
Intervention: 14-cores TRUS-guided biopsy (random technique)
Number of subjects: 100
Study 26717970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial corticosteroid injection
Number of subjects: 56
Study 26717970 — intervention group
Group type: COMPARATOR
Intervention: Blind subacromial corticosteroid injection
Number of subjects: 56
Study 24047110 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept MI (more intensive regimen)
Number of subjects: 456
Study 24047110 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept LI (less intensive regimen)
Number of subjects: 456
Study 24047110 — intervention group
Group type: COMPARATOR
Intervention: CsA (cyclosporine A)
Number of subjects: 456
Study 22071061 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA-only (10 mL, at 20 minutes)
Number of subjects: 270
Study 22071061 — intervention group
Group type: COMPARATOR
Intervention: CEI-only (10 mL/h)
Number of subjects: 270
Study 22071061 — intervention group
Group type: EXPERIMENTAL
Intervention: CEI + PCEA (CEI 10 mL/h plus PCEA 10 mL, at 20 minutes)
Number of subjects: 270
Study 18774947 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) training
Number of subjects: 29
Study 18774947 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) training
Number of subjects: 29
Study 16390353 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily for 6 days
Number of subjects: 10
Study 12734084 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (POC) with 14 mg/m(2) mitoxantrone infusion at the end of tumor excision
Number of subjects: 552
Study 12734084 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant treatment (including tamoxifen for postmenopausal women)
Number of subjects: 552
Study 11294543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular symphyseal bone
Number of subjects: 101
Study 11294543 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest cancellous bone
Number of subjects: 101
Study 8995348 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (Dios), two tablets/day for two months, in addition to compression therapy
Number of subjects: 107
Study 8995348 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (Dios)
Number of subjects: 107
Study 8995348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plac)
Number of subjects: 107
Study 8388353 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of Fraxiparin daily (group I)
Number of subjects: 253
Study 8388353 — intervention group
Group type: COMPARATOR
Intervention: No thromboprophylaxis (group II)
Number of subjects: 253
Study 2895594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 36
Study 2895594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 36
Study 2895594 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 36
Study 31906607 — intervention group
Group type: EXPERIMENTAL
Intervention: Median approach (Group M)
Number of subjects: 100
Study 31906607 — intervention group
Group type: COMPARATOR
Intervention: Paramedian approach (Group P)
Number of subjects: 100
Study 29431632 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of non-PV triggers (group A, n=250)
Number of subjects: 500
Study 29431632 — intervention group
Group type: COMPARATOR
Intervention: Stepwise substrate modification until noninducibility (group B, n=250)
Number of subjects: 500
Study 29431632 — intervention group
Group type: COMPARATOR
Intervention: Group B (stepwise substrate modification)
Number of subjects: 500
Study 29431632 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (elimination of triggers)
Number of subjects: 500
Study 28629419 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1219
Study 28629419 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers
Number of subjects: 1219
Study 26232172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (40 mg/kg every 8 hours for up to 6 doses)
Number of subjects: 208
Study 26232172 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (every 8 hours for up to 6 doses)
Number of subjects: 208
Study 26232172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 208
Study 26232172 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 208
Study 23515116 — intervention group
Group type: EXPERIMENTAL
Intervention: Family recommendations
Number of subjects: 250
Study 23515116 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived self-efficacy
Number of subjects: 250
Study 21353271 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy of albendazole, ivermectin, and praziquantel
Number of subjects: 235
Study 21353271 — intervention group
Group type: COMPARATOR
Intervention: Current NTD programme regimen (control)
Number of subjects: 235
Study 18348383 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (patch with extract of glycyrrhiza root)
Number of subjects: 69
Study 18348383 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 69
Study 18348383 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 69
Study 21429413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure (BIPAP) treatment
Number of subjects: 120
Study 21429413 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 15765952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber posts and composite
Number of subjects: 219
Study 15765952 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 219
Study 12446158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain group
Number of subjects: 0
Study 12446158 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 0
Study 9839760 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg donepezil for 28 days
Number of subjects: 16
Study 9839760 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg donepezil for 21 days after 7 days of 5 mg donepezil
Number of subjects: 16
Study 9839760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosage regimens (5 mg and 10 mg donepezil)
Number of subjects: 16
Study 8076659 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (delayed initiation beyond 24 hours and long-term maintenance treatment)
Number of subjects: 0
Study 8076659 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate aspirin and thrombolytic therapy
Number of subjects: 0
Study 8076659 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 2646383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy (A)
Number of subjects: 147
Study 2646383 — intervention group
Group type: COMPARATOR
Intervention: No pharyngeal surgery (NS)
Number of subjects: 147
Study 29987456 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone and mizoribine with warfarin and dipyridamole (group 1)
Number of subjects: 71
Study 29987456 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone and mizoribine without warfarin and dipyridamole (group 2)
Number of subjects: 71
Study 28325124 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetric gel
Number of subjects: 180
Study 28325124 — intervention group
Group type: COMPARATOR
Intervention: Control (no obstetric gel)
Number of subjects: 180
Study 28325124 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetric gel (among nulliparous women)
Number of subjects: 180
Study 28325124 — intervention group
Group type: COMPARATOR
Intervention: Control (no obstetric gel, among nulliparous women)
Number of subjects: 180
Study 26406148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg IV every 2 weeks)
Number of subjects: 821
Study 26406148 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (10 mg orally once daily)
Number of subjects: 821
Study 26406148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821
Study 26406148 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study 23701411 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg single-dose (150 mL)
Number of subjects: 100
Study 23701411 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg multiple-dose (150 mL once daily for 7 days)
Number of subjects: 100
Study 23701411 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg regimen
Number of subjects: 100
Study 21443305 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 393
Study 21443305 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 393
Study 19016090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for BN (duration not specified)
Number of subjects: 134
Study 17135619 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT; 80% maximum heart rate)
Number of subjects: 45
Study 17135619 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT; 10 repetitions at 80% maximum strength, two sets and eight exercises)
Number of subjects: 45
Study 17135619 — intervention group
Group type: COMPARATOR
Intervention: No Training (Control)
Number of subjects: 45
Study 14577344 — intervention group
Group type: EXPERIMENTAL
Intervention: DOT (Directly Observed Therapy) during admission
Number of subjects: 135
Study 14577344 — intervention group
Group type: COMPARATOR
Intervention: Non-DOT (self-administered therapy) during admission
Number of subjects: 135
Study 10918921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 0
Study 10918921 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 10918921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8878167 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (50 mg/mL, 216 mL/h)
Number of subjects: 24
Study 8878167 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (9 mg/mL, 3 mL · kg‐1 · h‐1)
Number of subjects: 24
Study 1613673 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (intravenous methylprednisolone 2 mg/kg body weight daily for 10 days)
Number of subjects: 59
Study 1613673 — intervention group
Group type: COMPARATOR
Intervention: Control (cotrimoxazole as standard treatment)
Number of subjects: 59
Study 1613673 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 59
Study 1613673 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 6439835 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (MFC + F): Induction therapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside followed by intermittent oral administration of 5-fluorouracil for two years.
Number of subjects: 243
Study 6439835 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (MF'C + F'): Ftorafur administered on the same schedule as regimen A.
Number of subjects: 243
Study 6439835 — intervention group
Group type: COMPARATOR
Intervention: Regimen C: Surgery alone (control).
Number of subjects: 243
Study 29371384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 14 days on/off
Number of subjects: 351
Study 29371384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 28 days on/off
Number of subjects: 351
Study 29371384 — intervention group
Group type: COMPARATOR
Intervention: Placebo 14 days on/off
Number of subjects: 351
Study 29371384 — intervention group
Group type: COMPARATOR
Intervention: Placebo 28 days on/off
Number of subjects: 351
Study 26938489 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-Based Glucose Management System (IBGMS)
Number of subjects: 182
Study 26938489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study 25033847 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 66
Study 25033847 — intervention group
Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 66
Study 25033847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 24358226 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group faces
Number of subjects: 0
Study 20113674 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage (with or without debridement at the clinical discretion of the surgeon)
Number of subjects: 0
Study 20113674 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 0
Study 20113674 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative management with specialist reassessment
Number of subjects: 0
Study 18468322 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthodontic treatments (specific interventions not detailed)
Number of subjects: 0
Study 18468322 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture hygiene and implants (commercially attractive topics)
Number of subjects: 0
Study 18468322 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16631060 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative sub‐Tenon's injection of triamcinolone (30 mg)
Number of subjects: 54
Study 16631060 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative sub‐Tenon's injection of triamcinolone (20 mg)
Number of subjects: 54
Study 16631060 — intervention group
Group type: COMPARATOR
Intervention: Steroid drops (control group)
Number of subjects: 54
Study 15446673 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-control intervention
Number of subjects: 45
Study 11704023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% aqueous timolol (timolol solution)
Number of subjects: 43
Study 11704023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol suspension (timolol gellan)
Number of subjects: 43
Study 11704023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9065721 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx 2 (high-dose carboplatin (HD-CBDCA) 500 mg/m2/day for 2 days and VP-16 100 mg/m2/day for 3 days)
Number of subjects: 46
Study 9065721 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx 3 (ifosfamide 1.5 g/m2/day for 3 days followed by carboplatin (CBDCA) 400 mg/m2 on day 4)
Number of subjects: 46
Study 9065721 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx 1 (high-dose cisplatin (HDP) 200 mg/m2 with concurrent sodium thiosulfate (STS) 9.9 g/m2 and etoposide (VP-16) 200 mg/m2/day for 3 days)
Number of subjects: 46
Study 9065721 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx 2 and Rx 3
Number of subjects: 46
Study 8213512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 20
Study 3318260 — intervention group
Group type: EXPERIMENTAL
Intervention: P-hGH
Number of subjects: 9
Study 3318260 — intervention group
Group type: EXPERIMENTAL
Intervention: B-hGH
Number of subjects: 9
Study 3318260 — intervention group
Group type: COMPARATOR
Intervention: im injection of hGH
Number of subjects: 9
Study 3318260 — intervention group
Group type: COMPARATOR
Intervention: sc injection of hGH
Number of subjects: 9
Study 31734701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Comprehensive Telerehabilitation (HCTR) program (1 week in hospital and 8 weeks at home)
Number of subjects: 850
Study 31734701 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 850
Study 28947165 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL retraining during PTA (treatment group)
Number of subjects: 104
Study 28947165 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone (control group)
Number of subjects: 104
Study 26704772 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIPPED scan
Number of subjects: 104
Study 26704772 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 104
Study 25552236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapro mesh
Number of subjects: 950
Study 25552236 — intervention group
Group type: COMPARATOR
Intervention: Prolene mesh
Number of subjects: 950
Study 25552236 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe preoperative pain
Number of subjects: 950
Study 23093054 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1500 IU) plus fluoxetine (20 mg)
Number of subjects: 42
Study 23093054 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine alone (20 mg)
Number of subjects: 42
Study 20466680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 32
Study 20466680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 32
Study 18181241 — intervention group
Group type: EXPERIMENTAL
Intervention: D-chlorpheniramine 6 mg
Number of subjects: 14
Study 18181241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16946391 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in UK journals
Number of subjects: 1135
Study 16946391 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in USA journals
Number of subjects: 1135
Study 16946391 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews in UK journals
Number of subjects: 1135
Study 16946391 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews in USA journals
Number of subjects: 1135
Study 16946391 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RCTs between UK and USA journals
Number of subjects: 1135
Study 16946391 — intervention group
Group type: COMPARATOR
Intervention: Comparison of systematic reviews between UK and USA journals
Number of subjects: 1135
Study 12749509 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg QD given i.v. and then orally for 7 to 15 days
Number of subjects: 438
Study 12749509 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg to 1 g i.v. every 6 to 8 hours, followed by oral ciprofloxacin 750 mg every 12 hours for 7 to 15 days
Number of subjects: 438
Study 10065749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 27
Study 10065749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7478123 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis starting 1 day after transplantation for 4 months
Number of subjects: 28
Study 7478123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 28
Study 2119524 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclate
Number of subjects: 0
Study 7386234 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 12